Clinical Trial Update: Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating immediate conversion from tacrolimus to everolimus in stable maintenance renal transplant recipients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Afinitor (everolimus)
• Prograf (Tacrolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Kidney Transplantation | Phase 4 | Status: WITHDRAWN